Adverum Biotechnologies Inc
(NASDAQ : AAVL)

( )
AAVL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.62%190.361.2%$564.46m
GILDGilead Sciences, Inc.
-0.52%70.550.9%$491.72m
BIIBBiogen Inc.
-1.73%313.551.3%$448.17m
CELGCelgene Corporation
-0.87%69.631.2%$426.13m
ILMNIllumina, Inc.
-0.95%308.233.5%$394.71m
REGNRegeneron Pharmaceuticals, Inc.
-1.41%337.292.6%$283.70m
VRTXVertex Pharmaceuticals Incorporated
-3.36%164.581.9%$265.75m
ALXNAlexion Pharmaceuticals, Inc.
-2.03%116.112.0%$195.76m
AAgilent Technologies, Inc.
-1.32%63.491.5%$175.37m
EXASExact Sciences Corporation
-1.38%68.4525.3%$145.96m
LGNDLigand Pharmaceuticals Incorporated
-0.42%147.8023.3%$142.63m
SRPTSarepta Therapeutics, Inc.
-4.09%111.9916.4%$134.89m
ECYTEndocyte, Inc.
-0.21%23.532.0%$121.26m
INCYIncyte Corporation
0.66%64.152.5%$116.78m
NKTRNektar Therapeutics
0.80%37.655.6%$109.74m

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.